Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Etanercept | |
| Synonyms |
Tumor Necrosis Factor Receptor IgG Chimera ETANERCEPT Enbrel Etanercept TNFR:Fc etanercept |
|
| Definitions |
A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2381 |
|
| Accepted_Therapeutic_Use_For |
juvenile arthritis; psoriatic arthritis; rheumatoid arthritis.
|
|
| ALT_DEFINITION |
A drug that is commonly used to treat arthritis. It is also being studied in the treatment of cancer, and as a treatment for loss of appetite and weight loss in cancer patients. It belongs to the family of drugs called tumor necrosis factor (TNF) antagonists.
|
|
| CAS_Registry |
185243-69-0
|
|
| code |
C2381
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC
|
|
| DEFINITION |
A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)
|
|
| Display_Name |
Etanercept
|
|
| FDA_UNII_Code |
OP401G7OJC
|
|
| FULL_SYN |
Tumor Necrosis Factor Receptor IgG Chimera ETANERCEPT Enbrel Etanercept TNFR:Fc etanercept
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Etanercept
|
|
| Legacy Concept Name |
Etanercept
|
|
| Maps_To |
Etanercept
|
|
| NCI_Drug_Dictionary_ID |
257809
|
|
| PDQ_Closed_Trial_Search_ID |
257809
|
|
| PDQ_Open_Trial_Search_ID |
257809
|
|
| Preferred_Name |
Etanercept
|
|
| prefixIRI |
Thesaurus:C2381
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0717758
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |